🔉 Major new funding for CEPI announced today. Ethiopia, Norway and the UK have pledged a combined US$240 million to support CEPI’s five-year plan to transform the world’s ability to prevent and respond to future epidemic and pandemic threats. cepi.net/ethiopia-nor...

Good decisions in an outbreak depend on good evidence. That’s why CEPI is investing US$3.9 million in three research projects to strengthen understanding of the Bundibugyo ebolavirus (BDBV) outbreak in the DRC, helping guide the response and support clinical trials of BDBV vaccine candidates ⬇️

New research set to strengthen epidemic intelligence and modelling for Bundibugyo virus response

CEPI is investing US$3.9 million in three research projects that will turn real-time outbreak data into actionable insights to guide the Bundibugyo ebolavirus response in the DRC and support vaccine t...

cepi.net

We’re thrilled to announce our new cohort of Fellows! Supported by @carnegie.org, this program builds biosecurity expertise by placing Fellows with leading global organizations to reduce biothreats. Read our full release ⤵️ pandemics.sph.brown.edu/news/2026-09...

Backed by an Award from the Andrew Carnegie Foundation, the Brown Pandemic Center Launches a New Fellowship to Advance Global Biothreat Reduction, New Cohort Announced

pandemics.sph.brown.edu

Today we announced new funding of up to US$8.9 million in Immunoscript Life Science to advance clinical testing of its thermostable next-generation self-amplifying RNA vaccine technology 🔽

India ramps up Disease X preparedness with $8.9 million funding boost for its freezer-free RNA vaccine

The funding will advance clinical testing of Immunoscript's thermostable next-generation RNA vaccine platform.

cepi.net

This week we hosted a landmark pandemic simulation exercise with Indonesia's Ministry of Health to strengthen national and regional readiness against a future ‘Disease X’. Discover more:

Indonesia steps up Southeast Asia’s outbreak preparedness with pandemic simulation exercise

Over 120 experts working across the vaccine and epidemic preparedness research ecosystem in Indonesia and the region are taking part in the table-top event in Jakarta.

cepi.net

As global leaders gather for the UN General Assembly High-Level Meeting on Pandemic Prevention, Preparedness and Response, CEPI invites you to join its flagship side event: Building Crisis-Ready Coalitions: From Fragmentation to Readiness. Register now: web-eur.cvent.com/event/44c8f5...

CEPI's August newsletter is now available ⬇️ This edition spotlights CEPI’s ongoing efforts to close the mpox vaccine access gap, the latest progress in the fight against Bundibugyo ebolavirus—including funding for a fifth vaccine candidate and the initiation of another Phase 1 trial—and lots more.

Closing the mpox vaccine access gap for mothers and young children

A new outbreak of mpox in Guinea-Bissau, the first recorded in the country, is a stark reminder that the virus remains a global threat. Mpox is not a new disease, but since the virus began spreading m...

linkedin.com

We've announced a new US$16.5 million partnership with African biopharmaceutical company Minapharm Group to develop their Bundibugyo vaccine candidate. The Bundibugyo epidemic in the DRC is the fastest-growing and second-largest Ebola outbreak on record: cepi.net/african-bund...

100 days into the Bundibugyo emergency, the global health response has moved at a pace unimaginable a decade ago. Yet the outbreak is far from contained. It's painful proof that in a deadly epidemic, even faster than ever is often not fast enough. ➡️ Read more on our website:

100 days into the Bundibugyo emergency, unprecedented speed is still not enough

The first 100 days of the Bundibugyo outbreak show how far epidemic response has advanced and how far it still has to go. It's painful proof that in a deadly epidemic, even faster than ever is often n...

cepi.net

Do existing vaccines against Zaire ebolavirus generate immune responses to Bundibugyo ebolavirus?

New studies to test whether existing Ebola vaccines can generate immune responses to Bundibugyo ebolavirus

CEPI-backed studies will analyse blood samples from thousands of people who have already been vaccinated against Zaire ebolavirus, with first results expected within months.

cepi.net

A new report from @pandemiccenter.bsky.social, @cepi.net, and @rand.org details key areas for defense and health investment to advance #100DaysMission and outlines recommendations for cross-sector collaboration to deliver faster pandemic preparedness and response. static.cepi.net/downloads/20...

We’re delighted to announce that the CEPI Board has appointed Professor Ibrahim Abubakar as CEPI’s next Chief Executive Officer. cepi.net/cepi-board-a...

The first participant has been dosed in a CEPI-backed Phase 1 trial of Moderna's investigational vaccine against Bundibugyo virus, marking rapid progress in the global effort to combat the deadly Ebola outbreak in DRC. Read more: cepi.net/modernas-bun...

The first participant has been dosed in a CEPI-backed Phase 1 trial of Moderna's investigational vaccine against Bundibugyo virus, marking rapid progress in the global effort to combat the deadly Ebola outbreak in DRC. Read more: cepi.net/modernas-bun...

🚨Last chance to apply! @cepi.net is seeking technical partners to support faster outbreak response by helping ensure critical biospecimens are available when needed. Apply by Aug 12: https://bit.ly/4hHQL5X #VaccinesWork

The Bundibugyo Ebola epidemic in the Democratic Republic of the Congo has passed a tragic milestone. Just 11 weeks after it was declared, the outbreak has reached 3,748 confirmed cases, making it the second-largest Ebola outbreak in history and the fastest-growing ever recorded.

CEPI's July newsletter is now available 🗞️ Explore the latest progress in the fight against the fastest-growing Ebola outbreak on record, along with new CEPI 3.0 campaign resources, open Calls for Proposals and lots more ⬇️

As Bundibugyo virus death toll mounts, hope is on the horizon

A tragic milestone was reached this month as the Bundibugyo ebolavirus outbreak – the fastest-growing Ebola outbreak on record - continues to escalate, with more than 1,400 deaths now recorded. As the...

linkedin.com

With the Bundibugyo outbreak the fastest-growing Ebola epidemic on record, CEPI is providing up to $8.5m to Hilleman Laboratories, a joint MSD-Wellcome Trust venture, to accelerate development and manufacture of an rVSV vaccine candidate for clinical trials. cepi.net/hilleman-lab...

Hilleman Laboratories to develop and produce CEPI-backed Bundibugyo ebolavirus vaccine doses for clinical trials

No vaccine is currently approved against the virus. The rVSV vaccine candidate could become an important tool for Bundibugyo outbreak control and response.

cepi.net

A powerful affirmation from Institut Pasteur de Dakar CEO Dr. Ibrahima Socé Fall, one of CEPI's key manufacturing partners, on the need for an organisation like CEPI and why continued investment in CEPI 3.0 is critical for our collective global health security ⬇️

The first volunteer has been vaccinated with the @ox.ac.uk's Bundibugyo ebolavirus vaccine candidate in a CEPI-backed clinical trial as efforts ramp up to contain a fast-spreading and deadly outbreak affecting the Democratic Republic of the Congo. Read more: www.ox.ac.uk/news/2026-07...

ICYMI: a CEPI-backed vaccine candidate developed by the University of Oxford became the first vaccine targeting Bundibugyo virus to enter Phase I trials, just 57 days after the WHO declared the outbreak a public health emergency. The Independent reports ⬇️

Oxford University begins human trials of new Ebola vaccine

The jab could be ready to send to the Democratic Republic of Congo within weeks

independent.co.uk

In our new blog, CEPI's Chief Scientific Writer Kate Kelland asked Aurélia Nguyen, CEPI’s Deputy CEO, to explain how CEPI is supporting the global response to the Bundibugyo outbreak and how that work aligns with the 100 Days Mission. Read the new Q&A to learn more: cepi.net/bundibugyo-a...

Bundibugyo and the 100 Days Mission: Preparedness, Readiness and Response

Aurélia Nguyen, CEPI’s Deputy CEO, explains how CEPI is supporting the global response to the Bundibugyo outbreak and how that work aligns with the 100 Days Mission.

cepi.net

CEPI has recently published its 2025 Annual Progress Report – a timely reflection of a year that reinforced why epidemic and pandemic preparedness is more important than ever. Read it here: static.cepi.net/downloads/20...

Our recent Innovations for Impact story takes a closer look at this clinical trial site in Bauchi, Nigeria, and the impact it is already helping to deliver in the region. Read it here ➡️ cepi.net/innovations-...

Outbreak ready, research ready: strengthening West Africa’s research ecosystem

CEPI’s Research Preparedness Programme is strengthening clinical trial infrastructure, systems and skills at frontline sites across West Africa.

cepi.net

MRC Unit The Gambia at LSHTM@mrcunitgambia.bsky.social · 3mo ago

We are excited to share the launch of the Abubakar Tafawa Balewa University Teaching Hospital clinical trial centre! Proud to have partnered with @cepi.net to strengthen #ClinicalTrials capacity & #EpidemicPreparedness efforts in #WestAfrica. #ClinicalResearch #Partnerships #ResearchCapacity

We are excited to share the launch of the Abubakar Tafawa Balewa University Teaching Hospital clinical trial centre! Proud to have partnered with @cepi.net to strengthen #ClinicalTrials capacity & #EpidemicPreparedness efforts in #WestAfrica. #ClinicalResearch #Partnerships #ResearchCapacity

CEPI has announced updates to its Scientific Advisory Committee, an external expert group providing independent scientific guidance across R&D programmes and outbreak preparedness activities. More: cepi.net/new-experts-...

New experts appointed to CEPI’s Scientific Advisory Committee

CEPI has announced updates to its Scientific Advisory Committee (SAC), an external expert group providing independent scientific guidance across R&D programmes and outbreak preparedness activities.

cepi.net

CEPI's latest newsletter is now available 🗞️ Dive in to explore the latest in epidemic and pandemic preparedness, including CEPI's Global Vaccine Manufacturing Summit, new investments to combat the Bundibugyo ebolavirus outbreak, CEPI 3.0 campaign updates and more.

Vaccine manufacturing: the bridge between science and impact

CEPI convened the Global Vaccine Manufacturing Summit 2026 in London, UK, on 17th June. For the first time, financing institutions, vaccine developers, regulators, manufacturers, philanthropies and gl...

linkedin.com

Earlier this month, researchers in our Preclinical Model and Centralised Laboratory Networks met up in Cape Town, South Africa, to discuss how they can strengthen collaboration and make the goal of developing a vaccine in 100 days a reality. Discover more in this Q+A: cepi.net/lab-scientis...

The lab scientists banding together to test new outbreak-busting vaccines

We're using knowledge built from the COVID-19 pandemic to strengthen the networks evaluating vaccine candidates that could fight the next big outbreak.

cepi.net

New funding from CEPI will help take a promising nanoparticle vaccine platform into early clinical development, with the aim of speeding up how we respond to future outbreaks. More ⬇️

CEPI funds next phase of nanoparticle vaccine platform to support rapid outbreak response

New funding will support the continued development of a pioneering vaccine platform.

cepi.net

🔉 CEPI is urgently accelerating the development of three investigational vaccine candidates towards clinical trials in response to the deeply concerning Bundibugyo ebolavirus epidemic. More in the press release ⬇️

CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates

CEPI funding will advance vaccine candidates towards clinical trials as quickly as possible.

cepi.net